An anti-cytokine bioactivity assay for interferons-α, -β and -ω

Journal of Immunological Methods

Volumn 195, Issue 1-2, 1996, Pages 55-61

  Mire Sluis, Anthony R ^a   Page, Lisa A ^a   Meager, Anthony ^a   Igaki, Janice ^b   Lee, Jamie ^b   Lyons, Sheila ^b   Thorpe, Robin ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b AMGEN INC   (United States)

Author keywords

Bioassay; Cytokine quantification; Interferon

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ARTICLE; BIOASSAY; CANCER IMMUNOTHERAPY; CELL LINE; CELL PROLIFERATION; ERYTHROLEUKEMIA; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL;

EID: 0030576930     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-1759(96)00092-0     Document Type: Article

References (35)

1. Adolf, G.R. (1990) Monoclonal antibodies and enzyme immunoassays specific for human Interferon (IFN) ω1: evidence that IFN-ω1 is a component of human leukocyte IFN. Virology 175, 410.
2. Daliani, D.D., Eisenberg, P.D., Weems, J., Lord, R., Fueger, R. and Logothetis, C.J. (1995) The results of a phase II randomized trial comparing 5-flurorouracil and 5-fluorouracil plus alpha-interferon: observations on the design or clinical trials for androgen-independent prostate cancer. J. Urol. 153, 1587.
3. Däubener, W., Wanagat, N., Pilz, K., Seghrouchni, S., Fischer, H.G. and Hadding, U. (1994) A new, simple, bioassay for human IFN-γ. J. Immunol. Methods 168, 39.
4. De Maeyer, E. and De Maeyer-Guignard, J. (1988) Interferons and Other Regulatory Cytokines. Wiley Interscience, New York,.
5. European Pharmacopoeia (1993) Statistical analysis of results of biological assays and tests. Pharmeuropa 6, 2nd edn., p. 81.
6. Fantes, K.H. (1966) Purification, concentration and physico-chemical properties of interferons. In: N.B. Finter (Ed.), Interferons. Elsevier/North-Holland, Amsterdam, p. 118.
7. Gasche, C., Reinisch, W., Vogelsang, H., Potzi, R., Markis, E., Micksche, M., Wirth, H.P., Gangl, A. and Lochs, H. (1995) Prospective evaluation of interferon alpha in treatment of chronic active Crohn's disease. Dig. Dis. Sci. 40, 800.
8. Grohn, P., Helle, L., Numminen, S. and Heinonen, E. (1994) Combination of carmofur and interferon-alpha 2b in advanced gastrointestinal cancer - a phase II pilot study. Acta Oncol. 33, 711.
9. Gutterman, J.U. (1994) Cytokine therapeutics: Lessons from interferon α. Proc. Natl. Acad. Sci. USA 91, 1198.
10. Halme, M., Maasilta, P., Mattson, K. and Cantell, K. (1994) Pharmacokinetics and toxicity of inhaled human natural interferon-beta in patients with lung cancer. Respiration 61, 105.
11. Hertzog, P.J., Johns, T.G., Callister, K.A., Dinatale, A. and Linnane, A.W. (1990) Comparative antiproliferative and receptor binding activities of interferons α and β on lymphoblastoid and melanoma cells. Biochem. Int. 22, 1095.
12. Ilson, D.H., Sirott, M., Saltz, L., Heelan, R., Huang, Y., Keresztes, R. and Kelsen, D.P. (1995) A phase II trial of interferon alpha 2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer 75, 2197.
13. Jaakkola, A., Anttila, P.M. and Immunen, I. (1994) Interferon alpha-2a in the treatment of exudative senile macular degeneration. Acta Ophthalmol. Copenh. 72, 545.
14. Johns, T.G., Mackay, I.R., Callister, K.A., Hertzog, P.J., Devenish, R.J. and Linnane, A.W. (1992) Antiproliferative protencies of interferons on melanoma cell lines and xenografts: Higher efficacy of interferon β. J. Natl. Cancer Inst. 84, 1185.
15. Kitamura, T., Tange, T., Terasawa, T., Chiba, S., Kuwaki, T., Miyagawa, K., Piao, Y.-F., Miyazono, K., Urabe, A. and Takaku, F. (1989) Establishment and characterisation of a unique human cell line that proliferates dependency on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 140, 323.
16. Komatsu, N., Yamamoto, M., Fujita, H., Miwa, A., Hatake, K., Endo, T., Okano, H., Katsube, T., Fukumaki, Y., Sassa, S. and Miura, Y. (1993) Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line. UT-7. Blood 82, 456.
17. Lewis, J.A. (1991) Antiviral activity of cytokines. In: F.R. Balkwill (Ed.), Cytokines - A Practical Approach. IRL Press, Oxford, p. 109.
18. Liberati, A.M., Horisberger, M.A., Garofani, P., De Angelis, V., Ferrajoli, A., Di Clemente, F., Caricchi, P., Adiuto, D., Fedeli, L. and Palumbo, B. (1994) Interferon alpha induced biologic modifications in patients with chronic myelogenous leukaemia. J. Interferon Res. 14, 349.
19. Meager, A. (1987) Quantification of interferons by anti-viral assays and their standardization. In: M.J. Clemens, A.G. Morris and A.J.H. Gearing (Eds.), Lymphokines and Interferons - A Practical Approach. IRL Press, Oxford, p. 129.
20. Mire-Sluis, A.R., Page, L. and Thorpe, R. (1995) Quantitative cell line based bioassays for human cytokines. J. Immunol. Methods 187, 191.
21. Nagata, S., Mantei, N. and Weissmann, C. (1980) The structure of one of the eight or more distinct chromosomal genes for human interferon-α. Nature 287, 401.
22. Nakayama, J., Takeuchi, M., Mayumi, H., Nagae, S., Matsuda, K., Yasui, H., Takahashi, S. and Hori, Y. (1994) Hyperthermic isolated limb perfusion with intra-arterial administration of carboplatin and/or interferon-beta for the treatment of malignant melanoma of the leg. J. Dermatol. 21, 915.
23. Panitch, H.S. and Bever, J.C.T. (1992) Clinical use of interferons in multiple sclerosis. In: S.E.A. Baron (Ed.), Interferons: Principles and Medical Applications. University of Texas Medical Branch, Galveston, TX, p. 581.
24. Pestka, S., Langer, J.A., Zoon, K.C. and Samuel, C.E. (1987) Interferons and their actions. Annu. Rev. Biochem. 56, 727.
25. Platanias, L.C. and Golomb, H.M. (1992) Clinical use of interferons: hairy cell, chronic myelogenous and other leukemias. In: S.E.A. Baron (Ed.), Interferon: Principles and Medical Applications. The University of Texas Medical Branch, Galveston, TX, p. 487.
26. Prümmer, O., Streichan, U., Heimpel, H. and Porzsolt, F. (1994) Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-α and IFN-β antibodies. J. Immunol. Methods 171, 45.
27. Randall, L.A., Wadhwa, M., Thorpe, R. and Mire-Sluis, A.R. (1993) A novel sensitive bioassay for transforming growth factor-beta. J. Immunol. Methods 164, 61.
28. Salpietro, F.M., Cipri, S., Alafaci, C., Tripodi, M., Alonci, A., Buda, G. and Tomasello, F. (1994) Combined systemic beta-interferon and thymostimulin administration for metastatic brain tumors - A brief report. J. Neurosurg. Sci. 38, 35.
29. Saven, A. and Piro, L.D. (1993) Treatment of hairy cell leukaemia. Blood 79, 1111.
30. 2. Science 209, 1343.
31. Taniguchi, T., Mantei, N., Schwarzstein, M., Nagata, S., Muramatsu, M. and Weissmann, C. (1980) Human leukocyte and fibroblast interferons are structurally related. Nature 285, 547.
32. The IFN-β Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655.
33. Torii, H., Kaneko, T., Matsuyama, T., Nakanishi, H. and Harada, S. (1994) Interferon alpha (IFN-alpha) and etretinate in the treatment of mycosis fungoides. J. Dermatol. 21, 767.
34. Walters, R.S., Theriault, R.L., Holmes, F.A., Esparza, L. and Hortobagyi, G.N. (1994) Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer. J. Immunother. Emphasis Tumor. Immunol. 16, 303.
35. Wong, V.L.Y., Rieman, D.J., Aronson, L., Dalton, B.J., Greig, R. and Anzano, M.A. (1989) Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines. Int. J. Cancer 43, 526.